The Joint Meeting of the American Academy of Sleep Medicine and Sleep Research Society (SLEEP)

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the need for improved tools to evaluate and treat sleep disorders in patients with Alzheimer disease. [WATCH TIME: 3 minutes]

The associate clinical professor at the University of South Carolina School of Medicine discussed how JZP-258’s clinical profile has expanded since its original approval for narcolepsy, and whether it makes sense for all patients to consider. [WATCH TIME: 3 minutes]

The associate clinical professor at the University of South Carolina School of Medicine provided context on 2 analyses presented at SLEEP 2022 that highlighted JZP-258’s impact in patients with idiopathic hypersomnia. [WATCH TIME: 2 minutes]

Patients with moderate-severe compared with normal-to-mild sleep disturbances had worse GAD-2 questionnaire scores, PHQ-2 scores, and PROMIS fatigue scores with no difference in age, sex, or hospitalization due to COVID-19.

The graduate student at the University of Michigan provided insight on her study examining longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders. [WATCH TIME: 3 minutes]

After 30 days of the PennPALS system, 70.8% of the remaining 24 patients were adherent to treatment or were using their PAP machine for at least 4 hours/night on average over the last 7 days.

The director of the Sleep Disorders program at the University of Miami discussed his research regarding the association of sleep disordered breathing and total brain volumes in Latino individuals. [WATCH TIME: 3 minutes]

The assistant professor of neurology at the University of Michigan provided context on a previous study which suggested that treatment of obstructive sleep apnea may reduce the risk of subsequent dementia. [WATCH TIME: 3 minutes]

Among those observed in the trial, Black pregnant women had a mean number of 4.20 sessions of cognitive behavioral therapy compared with 5.54 for White pregnant women.

In subanalyses of ISI responders with chronic insomnia, those in the lemborexant 10-mg group demonstrated significantly greater changes from baseline in sleep onset latency compared with placebo.

The IDSIQ showed score changes that correlated with clinically meaningful improvement on various responder definition estimates following triangulation.

A combination of less sleep and high cardiovascular disease risk tended to be associated with greater decline in executive function.

In comparison to White participants, non-Hispanic Black individuals reported shorter sleep duration and more sleep disturbances while the opposite was observed for Hispanic individuals.

Overall, 49% of respondents with idiopathic hypersomnia were reportedly dissatisfied with the management of their condition.

Although the sample size was relatively small, the findings provide insight into predictors of adherence to CPAP, which has been known to limit the effectiveness of the therapy.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Between those treated with CPAP and those who withdrew treatment, the difference in N3 sleep represented 15.7% of variance beyond a base model that included age and sex alone.

Avoidance of cardiovascular issues and effects, as well as improved effort to gain control of narcolepsy symptoms, were among the reasons for switching to lower sodium oxybate.

Data presented at SLEEP 2021 from Study 303 suggest that long-term use of lemborexant is well received by patients, who reported that the agent helped them fall asleep and improved total sleep time.

The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.

The Idorsia dual orexin receptor antagonist was accepted by the FDA for review in March 2021 and has shown efficacy in a number of SLEEP 2021 poster presentations.

The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.

The medical director of the Ohio State Sleep Medicine Institute detailed the progress made within the sleep disorder field in recent years and where it can turn to next.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.

The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.

Results from the START study of medication switching in narcolepsy were presented at the 2021 SLEEP Annual Meeting.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center discussed the formulaic background of FT218 and why it’s so effective in treating sleep disorders.

The FDA-approved agent demonstrated meaningful reduction in the frequency of cataplexy attacks in adults with narcolepsy, including patients with a high symptom burden.

Data presented at SLEEP 2021 also showed the treatment was associated with significant weight loss and reduction in BMI compared to placebo.

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.